$RPID

RAPID MICRO BIOSYSTEMS, INC.

CIK:0001380106|SEC Filings

Condensed consolidated statements of operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenue:
Total revenue	$ 8,054	$ 7,262	$ 16,056	$ 14,467
Cost of revenue:
Total cost of revenue	6,842	6,987	14,473	13,788
Gross margin	1,212	275	1,583	679
Operating expenses:
Research and development	3,332	3,230	6,691	6,854
Sales and marketing	3,436	3,114	6,858	5,865
General and administrative	6,766	6,079	14,208	11,769
Total operating expenses	13,534	12,423	27,757	24,488
Loss from operations	(12,322)	(12,148)	(26,174)	(23,809)
Other income (expense):
Interest income	140	351	396	817
Interest expense	(646)	(12)	(1,285)	(24)
Other expense, net	(50)	(38)	(82)	(87)
Total other income (expense), net	(556)	301	(971)	706
Loss before income taxes	(12,878)	(11,847)	(27,145)	(23,103)
Income tax expense	45	11	53	18
Net loss	$ (12,923)	$ (11,858)	$ (27,198)	$ (23,121)
Net loss per share — basic (in dollars per share)	$ (0.27)	$ (0.27)	$ (0.58)	$ (0.52)
Net loss per share — diluted (in dollars per share)	$ (0.27)	$ (0.27)	$ (0.58)	$ (0.52)
Weighted average common shares outstanding—basic (in shares)	48,346,663	44,648,602	47,008,322	44,321,566
Weighted average common shares outstanding—diluted (in shares)	48,346,663	44,648,602	47,008,322	44,321,566
Product
Revenue:
Total revenue	$ 5,286	$ 4,802	$ 10,864	$ 8,903
Cost of revenue:
Total cost of revenue	5,434	5,315	11,459	10,344
Service
Revenue:
Total revenue	2,768	2,460	5,192	5,564
Cost of revenue:
Total cost of revenue	$ 1,408	$ 1,672	$ 3,014	$ 3,444

Condensed consolidated statements of cash flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net loss	$ (27,198)	$ (23,121)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	1,380	1,658
Amortization of debt discount and issuance costs	171	0
Stock-based compensation expense	2,544	2,260
Provision for excess and obsolete inventory	10	441
Non-cash lease expense	609	609
Gain on revaluation of warrant liability	(118)	0
Accretion on investments	187	149
Other	115	36
Changes in operating assets and liabilities:
Accounts receivable	(2,381)	1,471
Inventory	(1,688)	(1,119)
Prepaid expenses and other current assets	82	182
Other long-term assets	3	0
Accounts payable	938	800
Accrued expenses and other current liabilities	(3,187)	(1,668)
Deferred revenue	773	(463)
Net cash used in operating activities	(27,760)	(18,765)
Cash flows from investing activities:
Purchases of property and equipment	(171)	(685)
Purchases of investments	(5,020)	(2,290)
Sales of investments	5,008	0
Maturity of investments	13,000	23,000
Net cash provided by investing activities	12,817	20,025
Cash flows from financing activities:
Proceeds from issuance of Class A common stock - stock option exercise	183	423
Proceeds from issuance of Class A common stock - employee stock purchase plan	140	90
Tax withholding on settlement of restricted stock units	0	(418)
Proceeds from related parties in underwritten and D&O offerings, net of underwriting discounts	9,395	0
Payments of third-party offering costs	(100)	0
Payments on finance lease obligations	(18)	(14)
Net cash provided by financing activities	9,600	81
Net (decrease) increase in cash, cash equivalents and restricted cash	(5,343)	1,341
Cash, cash equivalents and restricted cash at beginning of period	20,314	17,276
Cash, cash equivalents and restricted cash at end of period	14,971	18,617
Supplemental disclosure of cash flow information
Cash paid for interest	1,118	24
Supplemental disclosure of non-cash investing activities
Purchases of property and equipment in accounts payable and accrued expenses	0	75
Supplemental disclosure of non-cash financing activities
Offering costs included in accounts payable and accrued expenses	$ 409	$ 0

Condensed consolidated balance sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 14,687	$ 20,030
Short-term investments	5,079	18,266
Accounts receivable	5,515	3,134
Inventory, net	18,918	17,593
Prepaid expenses and other current assets	2,063	2,145
Total current assets	46,262	61,168
Property and equipment, net	8,161	8,972
Right-of-use assets	3,565	4,109
Other long-term assets	178	319
Restricted cash	284	284
Total assets	58,450	74,852
Current liabilities:
Accounts payable	5,177	4,139
Accrued expenses and other current liabilities	6,123	8,316
Deferred revenue	5,508	4,734
Lease liabilities, short-term	1,342	1,298
Total current liabilities	18,150	18,487
Notes payable, net	19,139	18,902
Warrant liability	68	186
Lease liabilities, long-term	2,997	3,674
Other long-term liabilities	348	397
Total liabilities	40,702	41,646
Commitments and contingencies (Note 15)
Stockholders’ equity:
Preferred stock, $0.01 par value: 10,000,000 shares authorized at June 30, 2026 and December 31, 2025; 0 shares issued and outstanding at June 30, 2026 and December 31, 2025	0	0
Additional paid-in capital	566,844	555,147
Accumulated deficit	(549,595)	(522,397)
Accumulated other comprehensive (loss) income	(1)	11
Total stockholders’ equity	17,748	33,206
Total liabilities and stockholders’ equity	58,450	74,852
Class A Common stock
Stockholders’ equity:
Common stock	455	400
Class B Common stock
Stockholders’ equity:
Common stock	$ 45	$ 45